Clinical Trials Search Results - Cone Health - Greensboro, NC

Skip to Content

Clinical Trials Search Results

Showing 1-10 of 22

Sorted By:

  • A081105

    Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

  • ACCRU RU011201I

    A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer.

  • Alliance A011202

    A randomized phase iii trial evaluating the role of axillary lymph node dissection in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy.

  • Alliance A031201

    Phrase III trial of Enzalutamide versus Enzalutamide, Abiraterone, and Prednisone for Castration Resistant Metastatic Prostate Cancer

  • Alliance A151216

    Genetic Testing For Patients with Resectable or Resected Lung Cancer

  • BMS CA209-370

    A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies.

  • CTSU E1A11

    Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

  • CTSU EA5142

    Nivolumab after Surgery and Chemotherapy in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer

  • Duke CaboMab

    Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer

  • ECOG E2112

    A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer

Page of 3, showing trials 1-10 of 22

Also in this Section